Kin Insurance vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 87)

Kin Insurance

LeaderInsurance Tech

General

Chicago DTC homeowners insurtech (founded 2016); $50M Series E $2B valuation (Sep 2025) total $476M raised, $495M premiums (+43%), 160K policyholders in cat markets, IPO filing planned 2025 competing with Hippo for catastrophe insurance.

AI VisibilityBeta
Overall Score
A87
Category Rank
#63 of 1167
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
83
Gemini
79

About

Kin Insurance is a Chicago, Illinois-based direct-to-consumer homeowners insurtech — having raised $476 million total including a $50 million Series E in September 2025 at a $2 billion pre-money valuation led by QED Investors and Activate Capital, plus $200 million in debt financing from Wellington Management — providing technology-driven homeowners insurance in catastrophe-exposed markets including Florida, Texas, California, Louisiana, Georgia, Alabama, Mississippi, South Carolina, Tennessee, Arizona, and Virginia where traditional insurers are retreating. Founded in 2016 by CEO Sean Harper, Lucas Ward, Sebastian Villarreal, and Stephen Wooten (entrepreneurs with fintech backgrounds from Groupon, Insight Venture Partners, and Avant), Kin operates as a Managing General Agent (MGA) writing policies on behalf of reciprocal exchanges it manages — a structure that gives Kin underwriting control and risk management authority while distributing policy risk through the reciprocal exchange mechanism rather than Kin's own balance sheet. In fiscal year 2024, Kin wrote $495.3 million in premiums (up 43% from $346.3 million in 2023), generated $156.1 million in total revenue (+48% YoY), served 160,000 policyholders (up from 115,000 in 2023), and the reciprocal exchanges it manages achieved their first full year of profitability with $12 million in operating income (+126%). The company's total insured property value surpassed $100 billion by April 2025, and Kin employs 800 people.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

87
Overall Score
90
#63
Category Rank
#9
73
AI Consensus
60
stable
Trend
stable
84
ChatGPT
99
83
Perplexity
99
79
Gemini
83
91
Claude
96
86
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.